Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Micron Technology, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Micron Technology, Inc. trades at $914 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 33.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MU | |
|---|---|---|
Market Cap | $29.60B | $980.90B |
Sector | Health | Technology |
52-Week High | $491.22 | $1.21K |
52-Week Low | $205.48 | $115.79 |
Enterprise Value | $27.56B | $961.25B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Micron Technology (MU) trades at $921.01, up 6.97% in 24 hours, with strong earnings beats in recent quarters and robust profitability metrics. Technical indicators show a bearish short-term signal, with the stock near resistance at $877. The company exhibits exceptional gross margins of 72.57% and net income margin of 55.91%, supported by surging memory demand and strategic customer agreements.
Outlook remains positive due to AI-driven memory demand and locked-in revenues, but risks include cyclical industry pressures and competitive threats. Analyst consensus is strongly bullish with an average price target of $1,540, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
